Because molecularly targeted drugs act on a specific molecule that plays an important role in cancer proliferation and survival, new drug development based on these somatic mutations is expected.p16 is one of the most studied biomarkers in lower anogenital tract squamous intraepithelial lesions25 and is overexpressed frequently (> 80%) in patients with ASCC. This evidence concerns the gene CDKN2A and cancer.